Agilent Technologies Reports 10% Revenue Growth to $1.835 Billion in Latest Quarter

Agilent Technologies, Inc. reported a net revenue of $1,835 million for the three months ended April 30, 2026, marking a 10% increase from $1,668 million in the same period last year. For the six months ended April 30, 2026, revenue rose 8% to $3,633 million compared to $3,349 million in the prior year. The company's net income for the quarter was $339 million, up from $215 million a year earlier, while net income for the six months increased to $644 million from $533 million. The growth in revenue was attributed to strong performance across all segments and geographic regions, with favorable foreign currency movements contributing 4 percentage points to quarterly growth and 3 percentage points to the six-month results.

Agilent's Life Sciences and Diagnostics Markets segment saw a 12% increase in revenue for the three months ended April 30, 2026, totaling $732 million, and an 8% increase for the six months, reaching $1,411 million. The Agilent CrossLab segment reported a 6% increase in quarterly revenue to $759 million and an 8% increase for the six months to $1,517 million. The Applied Markets segment experienced a 14% increase in quarterly revenue to $344 million and a 10% increase for the six months to $705 million. The overall revenue growth was driven by strong demand in key end markets, including pharmaceuticals and diagnostics.

In terms of operational developments, Agilent announced a definitive agreement to acquire BC Midco I, Inc. (Biocare) for approximately $950 million in cash, which is expected to enhance its Life Sciences and Diagnostics Markets segment. The acquisition is pending legal and regulatory approvals. Additionally, the company has been actively managing its costs amid ongoing geopolitical tensions and tariff uncertainties, implementing strategies such as supply chain optimization and targeted pricing actions to protect margins.

Agilent's total assets increased to $13,065 million as of April 30, 2026, up from $12,727 million at the end of the previous fiscal year. The company reported cash and cash equivalents of $1,807 million, a slight increase from $1,789 million. The employee headcount remained stable at approximately 18,000. The company also continued its share repurchase program, repurchasing 550,000 shares for $65 million during the quarter, and declared a quarterly dividend of $0.255 per share, totaling approximately $72 million.

Looking ahead, Agilent remains optimistic about long-term growth opportunities in its key markets, particularly in life sciences and diagnostics. The company plans to continue investing in research and development, enhancing its applications and solutions portfolio, and expanding its presence in developing markets. Despite the challenges posed by tariffs and geopolitical tensions, Agilent is focused on maintaining operational efficiency and delivering value to its customers.